Baseline plasma IL-18 may predict simvastatin treatment response in patients with ARDS: a secondary analysis of the HARP-2 randomised clinical trial

Background Interleukin (IL)-18 is a marker of inflammasome activation, and high baseline plasma IL-18 is associated with increased mortality in patients with sepsis-induced ARDS. The aim of this analysis was to determine if simvastatin was associated with benefit in patients with ARDS and high plasm...

Full description

Saved in:

Bibliographic Details
Published in:	Critical care (London, England) Vol. 26; no. 1; pp. 164 - 8
Main Authors:	Boyle, Andrew James, Ferris, Peter, Bradbury, Ian, Conlon, John, Shankar-Hari, Manu, Rogers, Angela J., O’Kane, Cecilia M., McAuley, Daniel F.
Format:	Journal Article
Language:	English
Published:	London BioMed Central 07.06.2022 BioMed Central Ltd Springer Nature B.V BMC
Subjects:	Acute respiratory distress syndrome Biological markers Carrier Proteins Clinical trials Complications and side effects Confidence intervals Critical care Critical Care Medicine Cytokines Drug therapy Emergency Medicine Health aspects Humans Inflammasome Inflammasomes Intensive Interleukin-18 Medicine Medicine & Public Health Mortality Patient outcomes Patients Personalised medicine Personalized medicine in the ICU Plasma Precision medicine Regression analysis Respiratory distress syndrome Respiratory Distress Syndrome - drug therapy Risk factors Sepsis Simvastatin Simvastatin - pharmacology Simvastatin - therapeutic use Statins Testing United Kingdom United Kingdom > UK Germany Acute respiratory distress syndrome Inflammasome Personalised medicine Interleukin-18 Simvastatin
ISSN:	1364-8535, 1466-609X, 1364-8535, 1466-609X, 1366-609X
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!